Evidence map›Paper›PMID 37719360›Full record

ArticleDrug design, development and therapy2023

Deciphering the Mechanism of Xijiao Dihuang Decoction in Treating Psoriasis by Network Pharmacology and Experimental Validation.

Yicheng Guo, Huiqun Gan, Shigui Xu, Guosheng Zeng, Lili Xiao, Zhijun Ding, Jie Zhu, Xinglong Xiong, Zhiyuan Fu

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yicheng GuoDepartment of Pharmacy, Dermatology Hospital of Jiangxi Province, Nanchang, People's Republic of China.ORCID 0000-0002-1255-8197
Huiqun GanDepartment of Pharmacy, Dermatology Hospital of Jiangxi Province, Nanchang, People's Republic of China.
Shigui XuDepartment of Pharmacy, Dermatology Hospital of Jiangxi Province, Nanchang, People's Republic of China.
Guosheng ZengJiangxi Provincial Clinical Research Center for Skin Diseases, Nanchang, People's Republic of China.
Lili XiaoJiangxi Provincial Clinical Research Center for Skin Diseases, Nanchang, People's Republic of China.
Zhijun DingJiangxi Provincial Clinical Research Center for Skin Diseases, Nanchang, People's Republic of China.
Jie ZhuCandidate Branch of National Clinical Research Center for Skin Diseases, Nanchang, People's Republic of China.
Xinglong XiongCandidate Branch of National Clinical Research Center for Skin Diseases, Nanchang, People's Republic of China.
Zhiyuan FuDepartment of Pharmacy, Dermatology Hospital of Jiangxi Province, Nanchang, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aims to confirm the efficacy of Xijiao Dihuang decoction (XJDHT), a classic prescription, in treating psoriasis and to explore the potential therapeutic mechanism. Methods: For pharmacodynamic analysis, a mouse model of imiquimod cream (IMQ)-induced psoriasis was constructed. Active ingredients and genes of XJDHT, as well as psoriasis-related targets, were obtained from public databases. Intersecting genes (IGEs) of XJDHT and psoriasis were collected by Venn Diagram. A protein-protein interaction (PPI) network of IGEs is constructed through the STRING database. The Molecular Complex Detection (MCODE) and Cytohubba plug-ins of Cytoscape software were used to identified hub genes. In addition, we conducted enrichment analysis of IGEs using the R package clusterProfiler. Hub genes were validated via external GEO databases. The influence of XJDHT on Hub gene expression was examined by qPCR and ELISA, and molecular docking was used to evaluate the binding efficacy between active ingredients and hub genes. Results: The results revealed that XJDHT possesses 92 potential genes for psoriasis, and 8 Hub genes were screened. Enrichment analysis suggested that XJDHT ameliorate psoriasis through multiple pathways, including AGE-RAGE, HIF-1, IL-17 and TNF signaling pathway. Validation data confirmed the differential expression of IL6, VEGFA, TNF, MMP9, STAT3, and TLR4. Molecular docking revealed a strong affinity between active ingredients and Hub genes. The efficacy of XJDHT in improving psoriatic lesions in model mice was demonstrated by PASI score and HE staining, potentially attributed to the down-regulation of VEGFA, MMP9, STAT3, TNF, and IL-17A, as evidenced by ELISA and qPCR. Conclusion: This study employed network pharmacology and in vitro experiments to identify the potential mechanisms underlying the therapeutic effects of XJDHT on psoriasis, providing a new theoretical basis for its clinical application in the treatment of psoriasis.

Indexed as

Network PharmacologyPsoriasisAnimalsDatabases, FactualMatrix Metalloproteinase 9MiceMolecular Docking SimulationMatrix Metalloproteinase 9angiogenesismolecular dockingnetwork pharmacologypsoriasisXijiao Dihuang decoction

Identifiers

PMID37719360
PMCPMC10504908

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.